Isogenica

Executive Summary

Isogenica is a UK-based biotechnology company that specializes in the discovery and engineering of VHH single-domain antibodies using the world's largest synthetic VHH libraries and its proprietary CIS Display™ technology. Founded in 2000 and headquartered in Cambridge, the company operates as a collaborative partner for biotech and pharmaceutical clients, offering custom antibody discovery services that accelerate therapeutic development from target to candidate. With a focus on high-quality, diverse libraries and efficient display technology, Isogenica enables the rapid identification of potent and developable single-domain antibodies for various therapeutic areas. Its platform is designed to overcome limitations of traditional antibody discovery, providing access to a vast repertoire of binders with favorable properties such as small size, stability, and ease of production.

Upcoming Catalysts (preview)

• TBDNew partnership or licensing deal with a pharmaceutical company60% success
• Q4 2026Advancement or expansion of CIS Display™ platform capabilities40% success
• TBDFunding round or strategic investment to support growth50% success